Dipeptidyl peptidase-4: difference between revisions
Diff·revision 12 → 13·04:50, 26 Dec 2024
Difference between revision 12 and revision 13 of Dipeptidyl peptidase-4. 3 lines changed; the page grew by 571 bytes.
| Revision 12 — 18:12, 3 Dec 2024 GIP_Genoveva (talk) convert the receptor-distribution list to a table 4,336 bytes +168 | Revision 13 — 04:50, 26 Dec 2024 ColdChainCleo (talk) expand §Catalytic action and substrate range 4,907 bytes +571 | ||
|---|---|---|---|
| 39 | | Fusion partner | [[Dulaglutide]] | Fc domain, plus Gly substitution | | 39 | | Fusion partner | [[Dulaglutide]] | Fc domain, plus Gly substitution | |
| 40 | 40 | ||
| + | 41 | Substitution alone is not sufficient for a long dosing interval — a DPP-4-resistant peptide is still cleared renally within hours — so the resistant residue is almost always combined with an [[Albumin binding half-life extension|albumin-binding]] or fusion strategy. Semaglutide combines both, and adds a substitution at position 34 to prevent acylation at the wrong lysine.{{r|knudsen2019}} | |
| + | 42 | ||
| 41 | == References == | 43 | == References == |
| 42 | {{reflist}} | 44 | {{reflist}} |
| 43 | <ref name="deacon2019">Deacon CF. "Physiology and pharmacology of DPP-4 in glucose homeostasis and the treatment of type 2 diabetes." ''Frontiers in Endocrinology'' 10:80 (2019). DOI:10.3389/fendo.2019.00080. PMID 30828317.</ref> | 45 | <ref name="deacon2019">Deacon CF. "Physiology and pharmacology of DPP-4 in glucose homeostasis and the treatment of type 2 diabetes." ''Frontiers in Endocrinology'' 10:80 (2019). DOI:10.3389/fendo.2019.00080. PMID 30828317.</ref> |
| 44 | <ref name="holst2007">Holst JJ. "The physiology of glucagon-like peptide 1." ''Physiological Reviews'' 87(4):1409–1439 (2007). PMID 17928588.</ref> | 46 | <ref name="holst2007">Holst JJ. "The physiology of glucagon-like peptide 1." ''Physiological Reviews'' 87(4):1409–1439 (2007). PMID 17928588.</ref> |
| + | 47 | <ref name="knudsen2019">Knudsen LB, Lau J. "The discovery and development of liraglutide and semaglutide." ''Frontiers in Endocrinology'' 10:155 (2019). PMID 31031702.</ref> | |
| 45 | 48 | ||
| 46 | == See also == | 49 | == See also == |